

Special Issue

HPV Vaccinations: Coverage, Challenges, and Strategies

Message from the Guest Editors

Despite the proven safety and efficacy of HPV vaccination, several barriers continue to hinder its universal implementation, including socioeconomic inequities, misinformation, gender bias, and programmatic challenges in reaching adolescents and underserved communities. Furthermore, there is a pressing need to optimize strategies for catch-up vaccination, integrate HPV vaccination within broader sexual and reproductive health programs, and evaluate long-term real-world effectiveness and immunological correlates of protection. This Special Issue aims to gather current evidence, innovations, and perspectives on HPV vaccination worldwide. We welcome original research, systematic reviews, and expert opinions that explore (i) global and regional trends in vaccine coverage, (ii) determinants of vaccine acceptance and hesitancy, (iii) health policy and implementation strategies to improve coverage, (iv) long-term impact and surveillance data, and (v) novel approaches to education, communication, and equity in HPV prevention.

Guest Editors

Dr. Gloria Calagna

"Villa Sofia Cervello" Hospital, University of Palermo, 90133 Palermo, Italy

Dr. Gabriela Paiva

Department of Gynecology and Obstetrics, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 22240-003, RJ, Brazil

Deadline for manuscript submissions

30 September 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/258450

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).